v3.26.1
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
1 Months Ended 9 Months Ended 12 Months Ended
Mar. 27, 2026
Jan. 16, 2026
Jan. 14, 2026
Nov. 04, 2025
Sep. 08, 2025
Feb. 10, 2025
Jan. 16, 2025
Nov. 22, 2024
Nov. 03, 2022
Jan. 31, 2026
Dec. 31, 2025
Mar. 31, 2026
Mar. 31, 2025
Nov. 25, 2025
Nov. 03, 2025
Mar. 31, 2024
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Sale of net proceeds                       $ 4,500,000 $ 18,858,000      
Share purchase value                       $ 8,135,000 2,151,000      
Warrants price                       $ 3.773        
Proceeds from private placement                       $ 90,000      
Share based compensation                       500,000 1,000,000.0      
Share compensation expense $ 100,000                     $ 5,282,000 9,146,000      
Warrants to purchase                       9,341,653        
Warrants Exercise                       $ 2,869,000 $ 365,000      
Restricted Stock Units (RSUs) [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Vesting period                       5 years        
Share-Based Payment Arrangement, Option [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Weighted average remaining service period                       1 year 6 months        
Option repricing       726,618                        
Incremental stock compensation expense                     $ 100,000 $ 300,000        
2025 Option Repricing [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Weighted average remaining service period                       1 year        
Unrecognized share based compensation                       $ 100,000        
Option exercise price               $ 10.80                
Stock based compensation                       300,000 1,600,000      
2013 Beyond Air Equity Incentive Plan [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Stock option shares authorized for issuance                         1,680,000 850,000    
Number of shares available for grant                         894,276      
Vesting period                       4 years        
Expiration period                       10 years        
Weighted average fair value of options                       $ 0.80 $ 5.03      
Option repricing                       756,749 739,219     566,645
Number of shares issued                       94,800 227,550      
2013 Beyond Air Equity Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Weighted average remaining service period                       1 year        
2013 BA Plan [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Share based compensation                       $ 300,000        
2013 BA EquityIncentivePlan [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Weighted average remaining service period                       1 year 8 months 12 days        
Unrecognized share based compensation                       $ 1,700,000        
2021 Beyond Cancer Ltd Equity Incentive Plan [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Stock option shares authorized for issuance                 4,000,000              
Number of shares available for grant                       1,745,500        
Vesting period                       4 years        
Weighted average remaining service period                       1 year        
Expiration period                       10 years        
Option repricing                       2,254,500 2,816,250     3,819,000
Number of additionl shares reserve for issuance                 2,000,000              
Unrecognized stock-based compensation expense                       $ 400,000        
Number of shares issued                            
2023 Neuro Nos Ltd Equity Incentive Plan [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Stock option shares authorized for issuance                         1,725,000      
Number of shares available for grant                       465,670        
Weighted average remaining service period                         1 year 6 months      
Weighted average fair value of options                       $ 2.38 $ 0.11      
Option repricing                       1,259,329 1,224,139    
Unrecognized stock-based compensation expense                         $ 100,000      
Number of shares issued                       169,913 1,224,139      
2021 Employee Stock Purchase Plan [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Number of shares issued                       0 0      
Private Placement [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Proceeds from private placement                       $ 4,500,000        
Commission paid                       300,000        
Other fees                       200,000        
Common Stock [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Share purchase value [1]                       $ 1,000      
Stock issues during the period, shares     524,990                 2,441,775 [1] 337,101 [1]      
Warrants price   $ 1.147 $ 1.272                          
Warrants to purchase   3,930,818                            
2026 Pre-funded Warrants [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Purchase warrants     $ 3,405,828                          
Warrants price   $ 0.0001 $ 1.2719                          
Warrant exercise price   $ 0.0001 $ 1.147                          
Warrants to purchase   3,405,828                            
Stock issued during the period, shares             1,263,215                  
2026 Common Warrants [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Purchase warrants     $ 3,930,818                          
Warrants price     $ 1.272                          
Pre-funded Warrants [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Proceeds from private placement     $ 5,000,000.0                          
Warrant [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Stock issues during the period, shares         719,562                      
Warrants price         $ 2.21                      
Warrant exercise price         $ 0.125                      
Other fees         $ 100,000                      
Warrants to purchase         1,439,128                      
Warrants Exercise         $ 2,900,000                      
Other fees         $ 200,000                      
Weighted average remaining service period         5 years                      
Maximum [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Public float value           $ 75,000,000.0                    
Minimum [Member] | Share-Based Payment Arrangement, Option [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Exercise price in excess       $ 1.95                        
Minimum [Member] | Common Stock [Member] | Beyond Cancer Ltd [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Fair value per share                       $ 3.00 $ 0.14      
2025 ATM [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Sale of Stock, Consideration Received Per Transaction           $ 35,000,000.0                    
Sale of stock fee percentage           2.50%                    
Sale of net proceeds                       $ 8,100,000        
Number of shares issued in transaction                       2,441,775        
2025 ATM [Member] | Common Stock [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Sale of net proceeds                         $ 2,100,000      
Number of shares issued in transaction                         337,100      
Purchase Agreement [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Share purchase value       $ 20,000,000                        
Stock issues during the period, shares       1,600,000           1,600,000            
Fair value per share                   $ 2.09            
Adjustments in additional paid in capital                   $ 3,300,000            
Common stock minimum purchase amount       $ 25,000                        
Beneficial ownership limitation percentage       4.99%                        
Amended Loan Agreement [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Warrants price                             $ 1.95  
Weighted average remaining service period                             5 years  
Amended Loan Agreement [Member] | Common Stock [Member]                                
Accumulated Other Comprehensive Income (Loss) [Line Items]                                
Warrants price                             $ 1.95  
Warrants to purchase                             512,821  
[1] Prior period results have been adjusted to reflect the one-for-twenty stock split in July 2025. See Note 1, Organization and Business for details.